Atlas Trials

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Clinical trial NCT02589496 · COMPLETED

Trial details

NCT number
NCT02589496
Sponsor
Samsung Medical Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Start date
2016-03-26
Primary completion
2021-12-01
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.